• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

56.69 +0.70 (+1.25%)
Official Closing Price Updated: 7:00 PM EDT, Apr 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,877,550
Open 56.01
Bid (Size) 55.33 (100)
Ask (Size) 57.88 (100)
Prev. Close 55.99
Today's Range 55.92 - 57.18
52wk Range 32.38 - 61.70
Shares Outstanding 5,385,189,617
Dividend Yield 3.43%
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer
April 02, 2026
BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster... 
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna 2.0: The mRNA Pioneer’s Pivot to Oncology and the Path to 2028 Profitability
March 31, 2026
As of March 31, 2026, Moderna Inc. (NASDAQ: MRNA) finds itself at a defining historical junction. After years of being defined by a single, world-altering product—its COVID-19 vaccine—the... 
Via Finterra
Topics Initial Public Offering

Performance

YTD
+14.2%
+14.2%
1 Month
-0.7%
-0.7%
3 Month
+14.2%
+14.2%
6 Month
+29.8%
+29.8%
1 Year
+50.6%
+50.6%

More News

Read More
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
March 27, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
March 16, 2026
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
The $40 Billion Pivot: Kimberly-Clark and Kenvue Merger Redefines the Consumer Staples Landscape
March 16, 2026
Via MarketMinute
Topics Artificial Intelligence Lawsuit
News headline image
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock ↗
March 16, 2026
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
News headline image
Amgen, GSK Set To Join TrumpRx Offering Deep Prescription Drug Discounts: Report ↗
March 16, 2026
Via Benzinga
News headline image
GSK’s RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk
March 13, 2026
From GSK plc
Via Business Wire
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
March 06, 2026
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
Moderna’s Renaissance: Why MRNA Surged 16% as the mRNA Platform Enters the Oncology Era
March 05, 2026
Via Finterra
Topics Intellectual Property
News headline image
Merck's Two-Drug HIV Regimen Challenges Industry Standards Following Positive Phase 3 Results
February 26, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
February 26, 2026
Via MarketMinute
Topics ETFs
News headline image
United Therapeutics (UTHR) Deep Dive: Strong Q4 and the ‘Inhalation Evolution’
February 26, 2026
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
Gilead’s Twice-Yearly HIV Breakthrough: A Paradigm Shift in Global Prevention and Market Dominance
February 25, 2026
Via MarketMinute
Topics Intellectual Property
News headline image
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
February 23, 2026
From Bora Pharmaceuticals Co., Ltd.
Via Business Wire
News headline image
GSK’s AREXVY Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
February 18, 2026
From GSK plc
Via Business Wire
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
February 17, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Moderna Shares Surge as Aggressive Cost-Cutting and Post-Pandemic Pivot Take Hold in Q4 Results
February 13, 2026
Via MarketMinute
Topics Earnings
News headline image
The Great 2026 Divergence: Tech Titans Rise on AI Execution While Healthcare Reaps a Regulatory Whirlwind
February 13, 2026
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
February 12, 2026
Via MarketMinute
Topics Earnings
News headline image
Incyte (INCY) Deep Dive: Navigating the 2026 Crossroads Following Earnings Miss
February 11, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
February 10, 2026
Via Finterra
Topics Economy Intellectual Property
News headline image
GSK (GSK) Q3 2025 Earnings Call Transcript ↗
February 05, 2026
Via The Motley Fool
Topics Earnings
News headline image
The Great Consolidation: US M&A Values Double as AI and Bio-Pharma Spark $2 Trillion Surge
January 26, 2026
Via MarketMinute
Topics Artificial Intelligence Economy

Frequently Asked Questions

Is GSK plc American Depositary Shares (Each representing two Ordinary Shares) publicly traded?
Yes, GSK plc American Depositary Shares (Each representing two Ordinary Shares) is publicly traded.
What exchange does GSK plc American Depositary Shares (Each representing two Ordinary Shares) trade on?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) trades on the New York Stock Exchange
What is the ticker symbol for GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
The ticker symbol for GSK plc American Depositary Shares (Each representing two Ordinary Shares) is GSK on the New York Stock Exchange
What is the current price of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
The current price of GSK plc American Depositary Shares (Each representing two Ordinary Shares) is 56.69
When was GSK plc American Depositary Shares (Each representing two Ordinary Shares) last traded?
The last trade of GSK plc American Depositary Shares (Each representing two Ordinary Shares) was at 04/02/26 07:00 PM ET
What is the market capitalization of GSK plc American Depositary Shares (Each representing two Ordinary Shares)?
The market capitalization of GSK plc American Depositary Shares (Each representing two Ordinary Shares) is 305.29B
How many shares of GSK plc American Depositary Shares (Each representing two Ordinary Shares) are outstanding?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) has 305B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap